scholarly journals Inflammatory bowel disease nurse specialists for patients on biological therapies: a nationwide Italian survey

2016 ◽  
Author(s):  
Alessandra Guarini
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Biological Therapies ◽  
Italian Survey ◽  
Inflammatory Bowel

Biological therapies for inflammatory bowel disease: controversies and future options

2009 ◽  
Vol 2 (4) ◽  
pp. 391-403 ◽  
Author(s):  
Alfredo Papa ◽  
Giammarco Mocci ◽  
Michele Bonizzi ◽  
Carla Felice ◽  
Gianluca Andrisani ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Biological Therapies ◽  
Inflammatory Bowel

scholarly journals Impact of biologics and small molecules for Inflammatory Bowel Disease on COVID-19 Related Hospitalization: A Systematic Review and Meta-analysis

2021 ◽  
Author(s):  
Fatema Alrashed ◽  
Hajer Alasfour ◽  
Mohammad Shehab
Keyword(s):  
Systematic Review ◽  
Inflammatory Bowel Disease ◽  
Relative Risk ◽  
Small Molecules ◽  
Bowel Disease ◽  
Biologic Therapy ◽  
Meta Analysis ◽  
Biological Therapies ◽  
Study Results ◽  
Inflammatory Bowel

Background The use of biological therapies and small molecules have been a concern for patients with inflammatory bowel disease (IBD) during COVID-19 pandemic. We aim to assess the association between risk of COVID-19 related hospitalization and these agents. Method A systematic review and meta-analysis of all published studies from December 2019 to September 2021 was performed to identify studies that reported COVID-19 related hospitalization in IBD patients receiving biological therapies or tofacitinib. The risk ratio (RR) was calculated to compare the relative risk of COVID-19 related hospitalization in patients receiving these medications to those who were not, at the time of the study. Results 18 studies were included. The relative risk of hospitalization was significantly lower in patients with IBD and COVID-19 who were receiving biologic therapy with RR of 0.47 (95% CI: 0.42-0.52, p < 0.00001). The RR was lower in patients receiving anti-TNFs compared to those who did not [RR= 0.48 (95% CI: 0.41-0.55, p < 0.00001)]. Similar finding was observed in patients taking ustekinumab [RR= 0.55 (95% CI: 0.43-0.72, p < 0.00001)]. Combination therapy of anti-TNF and an immunomodulator did not lower the risk of COVID-19 related hospitalization [RR= 0.98 (95% CI: 0.82-1.18, p =0.84]. The use of vedolizumab [RR= 1.13 (95% CI: 0.75-1.73, p =0.56] and tofacitinib [RR= 0.81 (95% CI: 0.49-1.33, p =0.40] was not associated with lower risk of COVID-19 related hospitalization. Conclusion Regarding COVID-19 related hospitalization in IBD, anti-TNFs and ustekinumab were associated with favorable outcomes. In addition, vedolizumab and tofacitinib were not associated with COVID-19 related hospitalization.

Biological Therapies For Inflammatory Bowel Disease: Research DrivesClinics

2006 ◽  
Vol 6 (7) ◽  
pp. 771-784 ◽  
Author(s):  
Silvio Danese ◽  
Stefano Semeraro ◽  
Alessandro Armuzzi ◽  
Alfredo Papa ◽  
Antonio Gasbarrini
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Biological Therapies ◽  
Disease Research ◽  
Inflammatory Bowel

Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies

2019 ◽  
Vol 206 ◽  
pp. 9-14 ◽  
Author(s):  
Konstantinos H. Katsanos ◽  
Konstantinos Papamichael ◽  
Joseph D. Feuerstein ◽  
Dimitrios K. Christodoulou ◽  
Adam S. Cheifetz
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Biological Therapies ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document